Immunomagnetic Reduction Detects Plasma Aβ1–42 Levels as a Potential Dominant Indicator Predicting Cognitive Decline

Shieh Yueh Yang; Huei Chun Liu; Wen Ping Chen

doi:10.1007/s40120-020-00215-2

Immunomagnetic Reduction Detects Plasma Aβ_1–42 Levels as a Potential Dominant Indicator Predicting Cognitive Decline

Shieh Yueh Yang^*, Huei Chun Liu, Wen Ping Chen

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

8 Citations (Scopus)

Abstract

Although the concentrations of Alzheimer’s disease (AD) biomarkers Aβ_1–40, Aβ_1–42 and tau protein are very low in human plasma, ultrasensitive assays such as immunomagnetic reduction (IMR) are able to precisely quantify them. Review articles have described the detailed working mechanism of IMR and revealed the feasibility of detecting early-stage AD by assaying these plasma biomarkers with IMR. In this review, we aimed to compare the significance of these plasma biomarkers in predicting cognitive decline in patients with Down syndrome, stroke, or amnestic mild cognitive impairment based on findings in the literature. We found that plasma Aβ_1–42 might play the predominant role in predicting cognitive decline in these patients.

Original language	English
Pages (from-to)	435-442
Number of pages	8
Journal	Neurology and Therapy
Volume	9
Issue number	2
DOIs	https://doi.org/10.1007/s40120-020-00215-2
Publication status	Published - 2020 Dec 1
Externally published	Yes

Keywords

Cognitive decline
Down syndrome
Immunomagnetic reduction
Plasma biomarkers
Stroke

ASJC Scopus subject areas

Neurology
Clinical Neurology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s40120-020-00215-2

Cite this

@article{40c283e2689f469c920ce1551bc3d7bb,

title = "Immunomagnetic Reduction Detects Plasma Aβ1–42 Levels as a Potential Dominant Indicator Predicting Cognitive Decline",

abstract = "Although the concentrations of Alzheimer{\textquoteright}s disease (AD) biomarkers Aβ1–40, Aβ1–42 and tau protein are very low in human plasma, ultrasensitive assays such as immunomagnetic reduction (IMR) are able to precisely quantify them. Review articles have described the detailed working mechanism of IMR and revealed the feasibility of detecting early-stage AD by assaying these plasma biomarkers with IMR. In this review, we aimed to compare the significance of these plasma biomarkers in predicting cognitive decline in patients with Down syndrome, stroke, or amnestic mild cognitive impairment based on findings in the literature. We found that plasma Aβ1–42 might play the predominant role in predicting cognitive decline in these patients.",

keywords = "Cognitive decline, Down syndrome, Immunomagnetic reduction, Plasma biomarkers, Stroke",

author = "Yang, {Shieh Yueh} and Liu, {Huei Chun} and Chen, {Wen Ping}",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = dec,

day = "1",

doi = "10.1007/s40120-020-00215-2",

language = "English",

volume = "9",

pages = "435--442",

journal = "Neurology and Therapy",

issn = "2193-8253",

publisher = "Springer Healthcare",

number = "2",

}

TY - JOUR

T1 - Immunomagnetic Reduction Detects Plasma Aβ1–42 Levels as a Potential Dominant Indicator Predicting Cognitive Decline

AU - Yang, Shieh Yueh

AU - Liu, Huei Chun

AU - Chen, Wen Ping

PY - 2020/12/1

Y1 - 2020/12/1

N2 - Although the concentrations of Alzheimer’s disease (AD) biomarkers Aβ1–40, Aβ1–42 and tau protein are very low in human plasma, ultrasensitive assays such as immunomagnetic reduction (IMR) are able to precisely quantify them. Review articles have described the detailed working mechanism of IMR and revealed the feasibility of detecting early-stage AD by assaying these plasma biomarkers with IMR. In this review, we aimed to compare the significance of these plasma biomarkers in predicting cognitive decline in patients with Down syndrome, stroke, or amnestic mild cognitive impairment based on findings in the literature. We found that plasma Aβ1–42 might play the predominant role in predicting cognitive decline in these patients.

AB - Although the concentrations of Alzheimer’s disease (AD) biomarkers Aβ1–40, Aβ1–42 and tau protein are very low in human plasma, ultrasensitive assays such as immunomagnetic reduction (IMR) are able to precisely quantify them. Review articles have described the detailed working mechanism of IMR and revealed the feasibility of detecting early-stage AD by assaying these plasma biomarkers with IMR. In this review, we aimed to compare the significance of these plasma biomarkers in predicting cognitive decline in patients with Down syndrome, stroke, or amnestic mild cognitive impairment based on findings in the literature. We found that plasma Aβ1–42 might play the predominant role in predicting cognitive decline in these patients.

KW - Cognitive decline

KW - Down syndrome

KW - Immunomagnetic reduction

KW - Plasma biomarkers

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85093514256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85093514256&partnerID=8YFLogxK

U2 - 10.1007/s40120-020-00215-2

DO - 10.1007/s40120-020-00215-2

M3 - Review article

AN - SCOPUS:85093514256

SN - 2193-8253

VL - 9

SP - 435

EP - 442

JO - Neurology and Therapy

JF - Neurology and Therapy

IS - 2

ER -